Compare BioNano Genomics Inc (BNGO) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs MasTec Inc — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while MasTec Inc trades at $280.16 (market cap $21.90B). The key difference: MasTec Inc is far larger — about 1603.2× BioNano Genomics Inc's market cap, and MasTec Inc is trading nearer its 52-week high, BioNano Genomics Inc nearer its low. Which is the better fit depends on your goals.
| BNGO | MTZ | |
|---|---|---|
Market Cap | $13.66M | $21.90B |
Sector | Health | Technology |
52-Week High | $4.92 | $437.51 |
52-Week Low | $1.06 | $172.51 |
Enterprise Value | $16.26M | $24.81B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
MasTec (MTZ) trades at $281.11, up 4.78% over 24 hours, amid strong 2026 performance with record Q2 revenue of $4.37 billion and a $21.4 billion backlog. Technical indicators show a bearish trend with resistance near $283, while fundamentals reflect robust growth—40% EBITDA growth in Q2—though valuation multiples like a P/E of 43.42 suggest premium pricing. Recent news highlights the acquisition of The Superior Group and a $650 million senior notes offering, bolstering infrastructure capabilities.
The outlook is positive, driven by infrastructure demand and raised 2026 guidance, but risks include execution challenges from acquisitions and communications segment delays. Analysts are overwhelmingly bullish with an 88.89% buy rating and a $439.56 consensus target, implying significant upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
